Loading clinical trials...
Loading clinical trials...
Study of the Expression of Angiotensin-converting Enzyme 2 (ACE2), a Cell Membrane Receptor for SARS-CoV-2 and the TMPRSS2 Serine Protease in Tonsils and Adenoids of Children and Adults
The objective of the research is to study the expression of the ACE 2 receptor and the TMPRSS2 serine protease in the tonsils and adenoids of children and adults.
The entry point for SARS-CoV-2 into the body is the nasal and pharyngeal mucosa. Angiotensin-converting enzyme 2 (ACE 2) was quickly identified as the functional receptor for SARS-CoV-2. Furthermore, the TMPRSS2 serine protease is required for the anchoring of the S protein in cell lines. In addition, the most commonly used screening test is a test for viral RNA by RT-PCR on a nasopharyngeal sample because the viral load is high. The tonsils and adenoids could be a target organ of the virus. In order to study this hypothesis, the expression of ACE 2 and the serine protease TMPRSS2 will be sought in these tissues. In addition, children, generally at high risk of severe viral respiratory infections (RSV, influenza), have milder symptoms than older patients with SARS-CoV-2 infection. The reason for this difference remains elusive. But one of the hypotheses formulated is that the level of expression of ACE 2 and / or TMPRSS2 may differ between adults and children, the viral load seeming to be correlated with the severity of the attack. In order to study this hypothesis, we will therefore compare the level of expression of ACE 2 in the tonsil tissue of children and adults.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Hôpital Mondor
Créteil, France
Hôpital Bicêtre
Le Kremlin-Bicêtre, France
Hôpital Lariboisière
Paris, France
Hôpital Armand Trousseau
Paris, France
Hôpital Pitié Salpêtrière
Paris, France
HEGP
Paris, France
Hôpital Necker-Enfants Malades
Paris, France
Hôpital Bichat
Paris, France
Hôpital Tenon
Paris, France
Start Date
June 30, 2021
Primary Completion Date
June 30, 2021
Completion Date
June 30, 2021
Last Updated
March 12, 2026
Storage of operating waste
OTHER
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
NCT06838260
NCT06339866
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07463482